目的探讨从免疫供血浆者获得高效价人破伤风抗体(抗TT)的免疫程序和免疫剂量,收集符合制备人破伤风免疫球蛋白标准的原料血浆。方法对适龄健康供血浆者按抗TT效价进行分组,对抗TT阴性供血浆者(抗TT<10mIU/ml)采用同一剂量吸附破伤风疫苗不同免疫程序进行免疫;对抗TT阳性供血浆者(抗TT≥10mIU/ml)采用不同剂量吸附破伤风疫苗和不同免疫程序进行免疫。采用ELISA定量检测其抗TT效价水平。抗TT效价≥8IU/ml的原料血浆可用于制备人破伤风免疫球蛋白[1]。结果抗TT阴性供血浆者组别相同剂量疫苗不同免疫程序产生高效价抗TT的比率差异无显著意义;抗TT阳性供血浆者组内免疫间隔短的组产生高效价人抗TT的比率明显高于免疫间隔长的组别;40IU剂量组抗TT持续>8IU/ml的比率高于20IU剂量组。结论采用40IU吸附破伤风疫苗,0、4周免疫抗TT阳性供血浆者可获得高效价抗TT原料血浆。 OBJECTIVE: To investigate the immunization procedure and immunological dose of high titer human tetanus antibody (anti-TT) from immunized blood plasma and collect the plasma of raw material meeting the standard of preparation human tetanus immunoglobulin. Methods Anti-TT titers were divided into groups according to their anti-TT titer, and were immunized with different immunization programs of the same dosage of tetanus vaccine against TT negative plasma (anti-TT <10mIU / ml) TT ≥ 10mIU / ml) Adopting different doses of tetanus vaccine and different immune programs for immunization. The anti-TT titer was detected by ELISA. Raw blood plasma with anti-TT titers> = 8 IU / ml can be used to prepare human tetanus immunoglobulin [1]. Results There was no significant difference in the rate of high titer of anti-TT among different anti-TT negative plasma donors with the same dose of vaccine and the high titer of human anti-TT in anti-TT positive plasma donors In the immunocompetent group, the 40 IU dose group had a higher anti-TT persistence> 8 IU / ml than the 20 IU dose group. Conclusion 40 IU tetanus toxoid vaccine was used to immunize TT-positive plasma at 0 and 4 weeks.